Overview

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Status:
Completed
Trial end date:
2007-02-08
Target enrollment:
Participant gender:
Summary
To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients. Also to assess the safety and tolerability of chronic oral lapatinib therapy in cancer patients.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Lapatinib
Midazolam